Peptides against autoantibodies associated with glaucoma and use of these peptides

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent covers novel peptides, corresponding nucleic acids, pharmaceutical compositions, and related devices that specifically bind to and neutralize autoantibodies linked with glaucoma, particularly those directed against the β2-adrenergic receptor. By mimicking the critical epitope (such as AINCYAN or ANETCCD sequence) of the receptor’s extracellular loop, these peptides can be used in diagnostic assays, therapeutic treatments (including in apheresis for antibody removal), and affinity chromatography devices. The invention also describes using these peptides in solid-phase systems for removing harmful autoantibodies from patient plasma and as therapeutics to treat or prevent glaucoma.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic removal or neutralization of pathogenic autoantibodies in glaucoma patients, especially by extracorporeal plasma apheresis using peptide-based columns.
• Diagnostic assays for the detection of autoantibodies against β2-adrenergic receptors in suspected glaucoma patients.
• Development of pharmaceutical compositions for therapy or prophylaxis of glaucoma by in vivo administration of peptides or their encoding nucleic acids.
• Screening of drugs targeting the interaction between autoantibodies and β2-adrenergic receptors to identify new therapeutics for glaucoma and related diseases.
• Use in personalized medicine approaches to better diagnose, risk-stratify, or monitor response to treatment in autoimmune-related glaucoma.
• Adaptation of the peptide/solid-phase technology for treatment or diagnosis of other autoimmune disorders involving pathogenic autoantibodies.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a targeted and novel therapeutic approach for glaucoma that addresses pathogenic autoantibodies, a mechanism not addressed by conventional pressure-lowering drugs.
• Enables more sensitive and specific diagnosis of autoimmune-related glaucoma, potentially leading to earlier and more effective intervention.
• Reduces the risk of vision loss or blindness in glaucoma patients by eliminating a causative factor (autoantibodies), which current therapies do not.
• Can be adapted for both in vivo (direct administration) and ex vivo (apheresis-based) therapeutic strategies.
• Offers a platform technology that could be expanded to other autoimmune diseases where pathogenic antibodies play a role.
• Offers the potential to develop safer and more compliant treatments compared to chronic use of eye drops or invasive surgery.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said peptides - especially in apheresis - for the treatment of glaucoma.